The next generation of single domain antibodies

From Target Identification To Bringing Drugs To Patients

A transformative platform that facilitates the advancement of next-generation therapies

To develop effective antibody-based therapeutic strategies, we must confront the challenges inherent in outdated discovery processes. The proprietary synthetic Single Domain Antibody (sd-Ab) libraries overcome the current barriers of conventional antibody discovery by providing unique targets and selecting humanized or fully human sd-Abs entirely in vitro. These sd-Abs are validated for a wide array of therapeutic applications, offering a distinct advantage in antibody development. Valour Bio represents a fusion of state-of-the-art technologies, providing a transformative platform for advancing next-generation therapies tailored to a wide range of indications.

This innovative amalgamation of techniques promises to revolutionize treatment by introducing novel, highly effective approaches, uniquely positioned to tackle the complex challenges. Next generation therapies will be at the forefront of this revolution.

Platform

V-LIB

2 humanized single domain libraries ;
Fully synthetic sd-Ab ;
Target identification (GPCR…) from patient samples

V-SCREEN

Functional screening ;
in vitro & in vivo validation.

V-ENGINE

Modulable ;
Specificity.

V-BODY

Small size ;
Robust ;
Low off-target ;
No aggregation ;

Multi-format including CAR, bispecific and ADC-based therapies.

Contact Us

Address

France:
49, boulevard du Général Martial Valin
75015, Paris, France

U.S.:
1 Hartwell Place.
Suite 305
Lexington, MA 02421

Phone 

France: +33 1 59 03 56 68
United States: +1 617.807.2062

Email

[email protected]